Magnesium.

Magnesium is required by the hepatic 25-hydroxylase and the renal 1-alpha-hydroxylase that activate vitamin D, and by the binding protein that transports it. Low magnesium status therefore blunts the rise in active vitamin D after supplementation. The relationship runs in the other direction too, since active vitamin D increases intestinal magnesium absorption.

Vitamin K2 carboxylates osteocalcin and matrix Gla protein, which govern where calcium is deposited, while magnesium is required for the enzymes and structural steps of bone matrix formation. The trio of D, K2 and magnesium is standard bone formula design for that reason. Bone mineral density is a marker measured over years, and none of these acts quickly.

At high single doses calcium and magnesium compete for shared paracellular and transcellular routes in the intestine, so very large simultaneous doses of both reduce the fractional absorption of each. At ordinary dietary intakes the interference is small. The practical answer is to split them across the day rather than avoid the combination.

Magnesium blocks the ROMK channel that leaks potassium into the urine, so when magnesium runs low the kidney wastes potassium. Potassium repletion that ignores magnesium status often fails for this reason. This is standard clinical electrolyte practice and applies to genuine depletion rather than to routine supplementation.

Pyridoxal kinase uses magnesium-ATP, so magnesium is required to phosphorylate B6 into its active coenzyme. The two have been paired in premenstrual and muscle formulas for decades. The cofactor relationship is settled biochemistry; claims for the specific combination in particular symptom sets are weaker than the biochemistry suggests.

ATP is biologically active as the magnesium chelate, and every kinase that moves a phosphate from ATP, creatine kinase included, works on Mg-ATP rather than free ATP. Magnesium is therefore a precondition for the phosphocreatine system rather than an addition to it. Magnesium creatine chelate exists as a single-ingredient version of the same idea.

Large zinc doses reduce magnesium absorption and balance, an effect described at supplemental rather than dietary zinc intakes. The competition is between divalent cations sharing intestinal handling. Separating the two doses across the day resolves it.

Non-heme iron and magnesium both use divalent cation handling in the gut and interfere when taken together in large amounts on an empty stomach. Iron is usually the more sensitive of the two. Spacing them by a few hours is the standard workaround.

Taurine influences intracellular calcium handling and membrane stability, which overlaps with magnesium's role as a physiological calcium antagonist at the cell membrane. They are commonly paired in cardiovascular and cramp formulas on that basis. The overlap is mechanistic and the human combination data is thin.

Glycine as a chelating ligand keeps magnesium soluble across the pH shift from stomach to small intestine and reduces the osmotic load that drives the laxative effect of poorly absorbed salts. Glycine also has its own presence in the nervous system, which is why the chelate is common in evening formulas. The ligand changes tolerability and dissolution behaviour, not the element itself.

Magnesium and melatonin appear together in most sleep formulas, and each has been studied separately for sleep measures. Direct evidence for the combination outperforming either alone is limited. Anyone stacking sedating ingredients should account for the total, not just each item.

Both appear in calming and evening blends and both are mild. Stacking several mild sedating ingredients produces a cumulative effect that is easy to underestimate, particularly alongside alcohol or prescription sedatives. There is little direct trial work on this specific pair.

Boron has been reported to reduce urinary magnesium and calcium losses in balance studies, which is the basis for its inclusion in bone formulas. The work is old, small and conducted in specific dietary settings. Read it as a retention signal rather than a settled effect.

Magnesium oxide and other poorly soluble salts depend on gastric acid to dissolve before absorption. Raising gastric pH with bicarbonate or an acid-reducing agent reduces the dissolved fraction from those salts. Pre-chelated forms are less dependent on gastric acid for the same reason.

Thiamine pyrophosphate-dependent enzymes, including pyruvate dehydrogenase and transketolase, require magnesium as the metal cofactor at the active site. Thiamine repletion in a magnesium-depleted state can therefore fail to restore enzyme activity. This is well recognised in clinical refeeding settings.

The hydroxylation steps that turn cholecalciferol into the active hormone are magnesium-dependent. That dependence is one plausible reason some people show a smaller than expected 25-hydroxyvitamin D response to a given dose. Serum 25-hydroxyvitamin D is a status marker, not an outcome.